Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial, which evaluated the use of cabozantinib+nivolumab in the treatment of advanced renal cell carcinoma.
Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial, which evaluated the use of cabozantinib+nivolumab in the treatment of advanced renal cell carcinoma.
Dr. Pedro Barata discusses the positive impact of cabozantinib+nivolumab treatment for high-risk patients with advanced renal cell carcinoma, including subgroups of patients with liver, lung, or bone metastases.
Dr. Yasser Ged discusses five-year follow-up data from the CheckMate-9ER trial, which studied the use of cabozantinib+nivolumab in patients with previously untreated advanced renal cell carcinoma.
Dr. Michael Devitt discusses the efficacy of cabozantinib as a first- and second-line treatment option for patients with advanced renal cell carcinoma (RCC).
©2025 Oncology Matrix. All Rights Reserved.
